With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.250285-32-6,1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride,as a common compound, the synthetic route is as follows.
In a 25 mL-volume Schlenk’s tube were placed 298 mg (0.10 mmol) of 1,3-bis(2,6-diisopropylphenyl)imidazolium chloride, 67.6 mg (0.70 mmol) of sodium t-butoxide, and 73.4 mg (0.74 mmol) of copper(I) chloride. The inner atmosphere was purged with Ar gas three times. To the content of the tube was added 5 mL of anhydrous tetra-hydrofuran (solvent) by means of a micro-syringe. The resulting mixture was stirred for 4 hours at room temperature. After the reaction was complete, the reaction mixture was filtered by celite to remove insolubles. The resulting solution was then concentrated. The concentrated product was brought into contact with a mixture of methylene chloride and diethyl ether, to precipitate 246 mg (0.50 mmol., yield 71%) of [1,3-Bis(2,6-diisopropyl-phenyl)imidazolium]copper(I) chloride as a white solid product. 1H-NMR (CD2Cl2, 300 MHz): 1.23 (d, 12H), 1.28 (d, 12H), 2.52-2.62 (m, 4H), 7.18 (s, 2H), 7.34 (d, 4H), 7.53 (dd, 2H) Elementary analysis: Found(%): C 66.44, H 7.28, N 5.77, Calculated(%) for C27H36ClCuN2: C 66.51, H 7.44, N 5.75, 250285-32-6
As the paragraph descriping shows that 250285-32-6 is playing an increasingly important role.
Reference£º
Patent; Ube Industries, Ltd.; US2005/90683; (2005); A1;,
Chiral Catalysts
Chiral catalysts – SlideShare